Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells

p53 Inhibits Angiogenesis by Inducing the Production of Arresten

(2012) S. Assadian et al.   CANCER RESEARCH

KR-POK Interacts with p53 and Represses Its Ability to Activate Transcription of p21WAF1/CDKN1A

(2012) B.-N. Jeon et al.   CANCER RESEARCH

p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors

(2012) Joern Henze et al.   PLoS One

Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer

(2011) Q. Chang et al.   CANCER RESEARCH

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

(2011) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

The ATM protein kinase and cellular redox signaling: beyond the DNA damage response

(2011) Scott Ditch et al.   TRENDS IN BIOCHEMICAL SCIENCES

p53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner

(2010) Y. Addadi et al.   CANCER RESEARCH

Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained

(2010) Jennifer S. Ko et al.   CANCER RESEARCH

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

(2010) Asfar S. Azmi et al.   EUROPEAN JOURNAL OF CANCER

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice

(2010) Mitomu Kioi et al.   JOURNAL OF CLINICAL INVESTIGATION

Role of Transcription Factors in Small Intestinal Ischemia-Reperfusion Injury and Tolerance Induced by Ischemic Preconditioning

(2010) M. Takeshita et al.   TRANSPLANTATION PROCEEDINGS

Tumor Vasculature Is Regulated by PHD2-Mediated Angiogenesis and Bone Marrow-Derived Cell Recruitment

(2009) Denise A. Chan et al.   CANCER CELL

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

(2009) J. M. L. Ebos et al.   CLINICAL CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis

(2009) Hong-li Yan et al.   EMBO JOURNAL

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

(2009) Ramzi M Mohammad et al.   Molecular Cancer

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

Regulation of MDMX Expression by Mitogenic Signaling

(2008) D. M. Gilkes et al.   MOLECULAR AND CELLULAR BIOLOGY

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA